- Home
- SNSE vs JAGX Comparison
SNSE vs JAGX Comparison
Compare SNSE & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- JAGX
- Stock Information
- Founded
- SNSE 2005
- JAGX 2013
- Country
- SNSE United States
- JAGX United States
- Employees
- SNSE N/A
- JAGX N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- JAGX Health Care
- Exchange
- SNSE Nasdaq
- JAGX Nasdaq
- Market Cap
- SNSE 10.8M
- JAGX 3.5M
- IPO Year
- SNSE 2021
- JAGX N/A
- Fundamental
- Price
- SNSE $8.17
- JAGX $2.70
- Analyst Decision
- SNSE Strong Buy
- JAGX Strong Buy
- Analyst Count
- SNSE 3
- JAGX 1
- Target Price
- SNSE $86.67
- JAGX $60.00
- AVG Volume (30 Days)
- SNSE 12.9K
- JAGX 86.9K
- Earning Date
- SNSE 08-05-2025
- JAGX 08-12-2025
- Dividend Yield
- SNSE N/A
- JAGX N/A
- EPS Growth
- SNSE N/A
- JAGX N/A
- EPS
- SNSE N/A
- JAGX N/A
- Revenue
- SNSE N/A
- JAGX $11,552,000.00
- Revenue This Year
- SNSE N/A
- JAGX $22.41
- Revenue Next Year
- SNSE N/A
- JAGX $30.00
- P/E Ratio
- SNSE N/A
- JAGX N/A
- Revenue Growth
- SNSE N/A
- JAGX 13.93
- 52 Week Low
- SNSE $5.00
- JAGX $2.43
- 52 Week High
- SNSE $17.40
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- SNSE 50.67
- JAGX 33.71
- Support Level
- SNSE $8.76
- JAGX $2.53
- Resistance Level
- SNSE $9.27
- JAGX $2.65
- Average True Range (ATR)
- SNSE 0.52
- JAGX 0.18
- MACD
- SNSE -0.00
- JAGX 0.14
- Stochastic Oscillator
- SNSE 42.84
- JAGX 31.03
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.